GlassScriptPhysician profile
Jenna Starko
NPI 1255769238
$1,656.24
in general payments reported to CMS, 2019-2025
27 companies · $24.87 in 2025
The $24.87 reported for 2025 was less than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $301 · 2022: $623 · 2023: $707 · 2025: $24.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $335.13 | 2023 | Xeomin |
| Myriad Genetic Laboratories, INC. | $182.11 | 2021-2023 | Myrisk |
| Novartis Pharmaceuticals Corporation | $156.79 | 2022-2025 | |
| Glaxosmithkline, LLC. | $92.66 | 2021-2022 | |
| Janssen Biotech, INC. | $82.55 | 2021-2023 | Erleada |
| Janssen Pharmaceuticals, INC | $80.40 | 2021-2022 | |
| Ethicon US, LLC | $64.67 | 2022-2023 | Stratafix, Vistaseal |
| Amgen INC. | $64.21 | 2022-2023 | Kyprolis |
| Pfizer INC. | $57.76 | 2022-2023 | |
| Morphosys, US INC. | $56.36 | 2021-2023 | Monjuvi |
| Eisai INC. | $54.38 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $48.08 | 2021 | |
| Merck Sharp & Dohme LLC | $41.97 | 2021 | |
| Seagen INC. | $38.18 | 2021-2022 | |
| Daiichi Sankyo INC. | $36.51 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $34.05 | 2022 | |
| Genmab U.S., INC. | $33.67 | 2022 | |
| Tactile Systems Technology INC | $26.81 | 2022 | |
| Cti Biopharma Corp. | $24.23 | 2023 | Vonjo |
| Rigel Pharmaceuticals, INC. | $22.04 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $21.86 | 2022 | |
| Taiho Oncology, INC. | $21.56 | 2023 | |
| Puma Biotechnology, INC. | $19.51 | 2023 | |
| Incyte Corporation | $18.73 | 2022 | |
| Myovant Sciences INC. | $17.05 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $12.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Starko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.